What development phase is Acetanil in?

Acetanil is FDA-approved (marketed).

What is the generic name of Acetanil?

ACETANILIDE is the generic (nonproprietary) name of Acetanil.

Last reviewed 2026-04-20 · How we verify

Acetanil (ACETANILIDE)

FDA-approved withdrawn Small molecule Quality 10/100

Acetanilide, a marketed drug, operates in a competitive landscape with several same-target drugs, including acetylsalicylic acid, benzoic acid, indomethacin, mefenamic acid, and oxyphenbutazone. Its key strength lies in the protection of its composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the presence of multiple off-patent competitors, such as mefenamic acid and oxyphenbutazone, which may limit its market share and revenue potential.

At a glance

Generic name	ACETANILIDE
Drug class	acetanilide
Target	Nicotinate phosphoribosyltransferase
Modality	Small molecule
Therapeutic area	Metabolic
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Delirium in Elderly Patients With Trauma of the Hip (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Acetanil CI brief — competitive landscape report
Acetanil updates RSS · CI watch RSS